Retension's $45M IPO Window Closes On Schedule
Retension Pharmaceuticals' upsized $45 million IPO was expected to close on or about Oct. 13, days after the hypertension-drug developer's shares began trading on Nasdaq.
Retension Pharmaceuticals (Nasdaq: RTSN) is a clinical-stage company developing RTN-001, an oral PDE-5 inhibitor for uncontrolled and resistant hypertension.
Retension Pharmaceuticals describes itself as a clinical-stage biopharmaceutical company focused on medicines for hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is described as a next-generation, once-daily, oral, small molecule PDE-5 inhibitor designed to lower blood pressure by boosting nitric oxide signaling.[1],[2]
The company says first-generation PDE-5 inhibitors were unable to meaningfully reduce blood pressure. It hypothesizes that this is due to limited distribution into the thicker, smooth muscle cell-rich central arteries. According to the company, RTN-001 was built with a proprietary surface chemistry platform meant to reach those tissues, including the aorta and the heart muscle.[1]
The company's stated strategy is to advance RTN-001 through clinical development in hypertension, study it in other diseases tied to nitric oxide signaling, and explore combinations with approved generic drugs. It also says it will consider partnerships and may expand its pipeline beyond RTN-001.[1]
RTN-001 is an investigational compound and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.[2],[1]
Retension says it was founded in 2023 by a leadership team with experience in surface chemistry technologies and small molecule drug discovery. RTN-001 was originally discovered and developed by Surface Logix, Inc., where members of the Retension team led its early development. The company says it holds an exclusive, worldwide, royalty-bearing license to the compound and keeps the clinical data from the nine completed trials run by Surface Logix.[1]
Eric Keller is chief executive. The company's news page lists the appointment of Alison Schecter, M.D., as chief medical officer and Alex Schwartz as chief financial officer. It also lists LeAnne Bloedon as executive vice president of clinical development and operations and Kevin Schutz as vice president of regulatory affairs, along with the formation of a scientific advisory board.[3],[4]
In its Series B release, Retension said RTN-001 had been studied in 243 human subjects, including two Phase 2 studies in patients with hypertension. A later release for its public offering gives the total as 265 enrolled subjects. Both counts come from the company, and it does not explain the difference.[4],[5],[1]
The company said the Phase 2b trial would be multicenter, double-blind, placebo-controlled and randomized, and would enroll approximately 280 patients. Retension said it would work with the Cleveland Clinic Coordinating Center for Clinical Research, and the release quotes Dr. Luke Laffin of the Cleveland Clinic. The company's news page says topline Phase 2b data are expected in the first half of 2027.[4],[3],[5]
Retension's news page lists a Series A that it described as oversubscribed, with a headline figure of $10.4 million. A later release announced the close of a $15 million Series B.[3],[4]
The company priced an upsized initial public offering of 3,750,000 shares at $12.00 per share, with expected gross proceeds of $45.0 million, according to its release hosted on BioSpace. The stock trades on the Nasdaq Capital Market under the ticker RTSN. Leerink Partners, Guggenheim Securities and Oppenheimer & Co. were joint bookrunning managers, and Titan Partners was lead manager.[5]
The company said it would use the net proceeds to complete the Phase 2b trial and to prepare for a planned Phase 3 trial, with the remainder for general corporate purposes. Its news page later reported that the October 2026 upsized offering generated $51.75 million in gross proceeds. That figure is higher than the $45.0 million in the pricing release, and the news page summary does not explain the gap.[5],[3],[4]
Is something wrong on this page?
| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Oct 7, 2026 | ipo | — | — | SEC |
Retension Pharmaceuticals' upsized $45 million IPO was expected to close on or about Oct. 13, days after the hypertension-drug developer's shares began trading on Nasdaq.
Days after Nvidia-backed Firmus withdrew its roughly $31 billion-valuation IPO on market-turbulence grounds, two much smaller biotechs, TRex Bio and Retension Pharmaceuticals, priced their own IPOs anyway -- for a combined $161.7 million.
Retension Pharmaceuticals priced an upsized IPO at $12.00 per share for $45 million in gross proceeds, days after amending its S-1 for a second time, with shares trading on Nasdaq as RTSN.

Retension Pharmaceuticals filed a second S-1/A amendment on Oct. 7, two days after its first amendment, continuing to move its IPO registration through SEC review since Pulse first covered its original filing in September.
TRex Bio and Retension Pharmaceuticals both filed S-1 registration statements for Nasdaq IPOs on the same day, joining a fall biotech listing wave with Eli Lilly backing TRex's autoimmune-disease pipeline.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.